• Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China;
Sun Xiaodong, Email: xdsun@sjtu.edu.cn
Export PDF Favorites Scan Get Citation

The application of gene therapy in ocular diseases is gradually expanding from mono-gene inherited diseases to multigene, multifactorial, common and chronic diseases. This emerging therapeutic approach is still in the early exploratory stage of treating diseases, and the expected benefits and risks remain highly uncertain. In the delivery process of gene therapy drugs, viral vector is currently one of the most mature and widely used vectors. The occurrence of vector-associated immunity will affect the short-term and long-term effects of gene therapy, and even cause permanent and serious damage to visual function. Therefore, gene therapy vector-associated immunity is the focus and challenge for the safety and long-term efficacy of gene therapy. During the perioperative and follow-up of gene therapy, attention should be paid to the monitoring of vector-associated immune inflammation, and appropriate measures should be taken to deal with the corresponding immune response, so as to achieve the best visual benefits for patients.

Citation: Sun Xiaodong, Chen Jieqiong. Pay attention to the detection and treatment of ocular gene therapy viral vector-associated immunity. Chinese Journal of Ocular Fundus Diseases, 2022, 38(8): 621-625. doi: 10.3760/cma.j.cn511434-20220629-00389 Copy

  • Previous Article

    Pay more attention to several issues in genetic diagnosis for patients with inherited retinal diseases
  • Next Article

    Expert consensus and recommendations on the evaluation of visual function and outcome measurements in clinical trials for inherited retinal diseases in China